Drug Profile
Belotecan - Chong Kun Dang Pharmaceutical
Alternative Names: Belotecan hydrochloride; Camtobell; CKD 602; EQ-917; S-CKD602Latest Information Update: 10 Jul 2019
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Developer Chong Kun Dang; Chonnam National University Hospital; OnKor Pharmaceuticals
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 10 Jul 2019 No development reported - Phase-II for Ovarian cancer (Recurrent, Second-line therapy or greater) in South Korea (IV) (NDR batch #16)
- 13 Aug 2015 Phase-IIb development for Ovarian cancer (Recurrent, Second-line therapy or greater) is ongoing in South Korea (NCT01630018)
- 13 Aug 2015 No recent reports on development identified - Phase-I for Solid tumours in South Korea (PO)